Small-Cap Investor Forum

[25 Kilos of Gold]

CTIX. Monster 10K report today. http://www.sec.gov/Archives/edgar/data/1355250/000147793214005027/ctix_10k.htm
Tue, 09 Sep 2014 19:00:00 GMT ~ Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application to FDA for Phase 2 Trial of Brilacidin-OM for Oral Mucositis
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce this update on its recently ...
read full: http://finance.yahoo.com/news/cellceutix-provides-initial-observations-completed-190000867.html
*********************************************************
Fri, 05 Sep 2014 15:15:46 GMT ~ Cellceutix to Present at Rodman & Renshaw's 16th Annual Global Investment Conference
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announced today that Leo Ehrlich, CEO will be ...
read full: http://finance.yahoo.com/news/cellceutix-present-rodman-renshaws-16th-151546102.html
*********************************************************
Tue, 02 Sep 2014 11:00:00 GMT ~ Cellceutix Appoints Dr. Barry Schechter to Board of Directors as Company Focuses on Meeting Requirements for Stock Exchange Uplisting
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce the appointment of Dr. ...
read full: http://finance.yahoo.com/news/cellceutix-appoints-dr-barry-schechter-110000360.html
*********************************************************
Tue, 02 Sep 2014 10:29:26 GMT ~ CELLCEUTIX CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statements and

read full: http://biz.yahoo.com/e/140902/ctix8-k.html
*********************************************************
Tue, 19 Aug 2014 12:30:00 GMT ~ Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)